SCHEMBL5845392

SCHEMBL5845392

CN1CCCC1CCNc1nc(C2(c3ccc(Cl)cc3)CCCCC2)cs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.46
CAMK2D Q13557 1/20 0.40
ACP1 P24666 2/20 0.40
HRH1 P35367 3/20 0.38
HRH3 Q9Y5N1 3/20 0.38
HRH2 P25021 2/20 0.38
ACKR3 P25106 1/20 0.38
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
DCAF15 Q66K64 2/20 0.37
JAK1 P23458 1/20 0.37
KCNH2 Q12809 2/20 0.36
ADRA1A P35348 2/20 0.36
CHRM3 P20309 2/20 0.36
SLC22A1 O15245 1/20 0.36
MLNR O43193 1/20 0.36
NR1I2 O75469 1/20 0.36
TP53 P04637 1/20 0.36
ADRB2 P07550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845190 0.97 BACE1 (0.44) BACE1CAMK2DACP1HRH1HRH3
SCHEMBL5845604 0.92 BACE1 (0.39) BACE1CAMK2DACP1HRH1HRH3
SCHEMBL6774774 0.81 ACKR3 (0.41) ACP1HRH1HRH3HRH2ACKR3
SCHEMBL5846112 0.79 BACE1 (0.49) BACE1KCNH2NR1I2SIGMAR1
SCHEMBL5846154 0.78 BACE1 (0.44) BACE1DRD2TSHRSIGMAR1
SCHEMBL5845387 0.77 BACE1 (0.48) BACE1HRH1HRH3HRH2DCAF15
SCHEMBL5844691 0.76 BACE1 (0.47) BACE1HRH3
SCHEMBL5846203 0.75 BACE1 (0.46) BACE1KCNH2HTR1ATSHRMTOR
SCHEMBL5845663 0.74 ALOX5AP (0.44) CAMK2DACP1HRH1HRH3HRH2
SCHEMBL5845599 0.73 BACE1 (0.45) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087623-B2 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof SEPRACOR INC. (US) 2006-08-08 US disclosed
US-20040235913-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof CUNY GREGORY D (US) 2004-11-25 US disclosed
US-6699866-B2 FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS SEPRACOR INC. 2004-03-02 US disclosed
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-06-05 US disclosed
WO-2002083863-A2 THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF SEPRACOR, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235913-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof HTR5A, OPRL1, HTR2C BACE1 358/4885CAMK2D 3149/4885ACP1 4437/4885
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof HTR5A, OPRL1, HTR2C BACE1 358/4885CAMK2D 3149/4885ACP1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.